Overview of the Current Situation and Challenges about Neuromyelitis Optica Spectrum Disorders in the Republic of Macedonia
DOI:
https://doi.org/10.3889/oamjms.2020.4329Keywords:
neuromyelitis optica spectrum disorders, unmet need, challenges, Devic disease, neuromyelitis optica spectrum disorders (NMOSD)Abstract
BACKGROUND: Neuromyelitis optica spectrum disorders (NMOSD) are rare, progressive inflammatory disorders of the central nervous system characterized by severe, immune-mediated demyelination targeting optic nerves and spinal cord. Prior establishment of diagnostic criteria, patients were often misdiagnosed which led to delayed/inappropriate treatment and disability. Current practice involving immunotherapies is insufficient. Recent data are encouraging since the novel treatments allow effective prevention.
AIM: The primary objective was to evaluate the current situation to identify challenges and develop intervention that might improve the current state as secondary objectives.
METHODS: Standard questionnaire containing 22 questions was developed. Collected data were analyzed and descriptive report was created.
RESULTS: Current estimated prevalence is approximately 20 NMOSD patients; trend is unknown due unavailability of patient registry. Six neurologists from one health-care institution are responsible for the whole management. Despite physician’s insufficient experience, ~80% of them are willing to switch patients into innovative treatments once available. Aquaporin-4-IgG testing is not routinely available resulting in ~30% testing rate. Approximately 80–90% of patients are on maintenance treatment with immunosuppressant, corticosteroids are used for acute relapse. Lack of novel innovative medications is evident.
CONCLUSION: Current NMOSD management is challenging with significant unmet needs. Highest priorities that might provide improvement are: APQ4-IgG testing availability, establishment of patient registry, and availability of novel treatments.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Devic E. Myélite aiguë compliquée de névrite optique. Bull Med (Paris). 1894;8:1033.
Gault F. De la Neuromyélite Optique Aiguë, Thesis, Lyon; 1894.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-15. PMid:17706564
Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic’s neuromyelitis optica: A clinicopathological study of 8 patients. Ann Neurol. 1993;34(2):162-8. https://doi.org/10.1002/ana.410340211 PMid:8338340
Wingerchuk DM. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol Res. 2006;28(3):348-53. PMid:16687064
Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;125(Pt 7):1450-61. https://doi.org/10.1097/00041327-200306000-00040 PMid:12076996
Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology. 2004;63(12):2363-70. https://doi.org/10.1212/01.wnl.0000148481.80152.bf PMid:15623701
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-12. https://doi.org/10.1016/s0140-6736(04)17551-x PMid:15589308
Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain. 2007;130(Pt 5):1235-43. https://doi.org/10.1093/brain/awm062 PMid:17449477
Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131(Pt 11):3072-80. https://doi.org/10.1093/brain/awn240 PMid:18945724
Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019-32. https://doi.org/10.1111/j.1468-1331.2010.03066.x PMid:20528913
Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009;66(5):617-29. https://doi.org/10.1002/ana.21802 PMid:19938104
Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients. Neurology. 2012;78(20):1601-7. https://doi.org/10.1212/wnl.0b013e31825644ff PMid:22551731
Iyer A, Elsone L, Appleton R, Jacob A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity. 2014;47:154-61. https://doi.org/10.3109/08916934.2014.883501 PMid:24512514
Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: A multicenter analysis. Arch Neurol. 2012;69(9):1176-80. https://doi.org/10.1001/archneurol.2012.314 PMid:22733096
Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, Lara-RodrÃguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol. 2009;256(1):35-44. https://doi.org/10.1007/s00415-009-0009-0 PMid:19224310
Uzawa A, Mori M, Kuwabara S. Neuromyelitis optica: Concept, immunology and treatment. J Clin Neurosci. 2014;21(1):12-21. https://doi.org/10.1016/j.jocn.2012.12.022 PMid:23916471
Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76(18):1589-95. https://doi.org/10.1212/wnl.0b013e3182190f74 PMid:21536639
Flanagan EP, Cabre P, Weinshenker BG, St Sauver J, Jacobson DJ, Majed MM, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016;79(5):775-83. PMid:26891082
Bukhari W, Prain KM, Waters P, Woodhall M, O’Gorman CM, Clarke L, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry. 2017;88(8):632-8. PMid:28550069
Miyamoto K, Fujihara K, Kira JI, Kuriyama N, Matsui M, Tamakoshi A, et al. Nationwide epidemiological study of neuromyelitis optica in Japan. J Neurol Neurosurg Psychiatry. 2018;89(6):667-8. https://doi.org/10.1136/jnnp-2017-317321 PMid:29326292
Mori M, Kuwabara S, Paul F. Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89:555-6. https://doi.org/10.1136/jnnp-2017-317566 PMid:29436488
Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018;91(22):e2089. PMid:30366977
Ghezzi A, Bergamaschi R, Martinelli V, Trojano M, Tola MR, Merelli E, et al. Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica. J Neurol. 2004;251(1):47-52. https://doi.org/10.1007/s00415-004-0271-0 PMid:14999489
Wingerchuk DM. Neuromyelitis optica: Effect of gender. J Neurol Sci. 2009;286(1-2):18-23. PMid:19740485
Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Clinical spectrum of CNS aquaporin-4 autoimmunity. Neurology 2012;78(15):1179-85. PMid:22459676
Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53(5):1107-14. https://doi.org/10.1212/wnl.53.5.1107 PMid:10496275
Drori T, Chapman J. Diagnosis and classification of neuromyelitis optica (Devic’s syndrome). Autoimmun Rev. 2014;13(4-5):531-3. PMid:24424197
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89. PMid:26092914
Collongues N, de Seze J. Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord. 2011;4(2):111-21. https://doi.org/10.1177/1756285611398939 PMid:21694808
Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the neuromyelitis optica study group (NEMOS). J Neurol. 2014;261(1):1-16. https://doi.org/10.1007/s00415-013-7169-7 PMid:24272588
Sherman E, Han MH. Acute and chronic management of neuromyelitis optica spectrum disorder. Curr Treat Options Neurol. 2015;17(11):48. https://doi.org/10.1007/s11940-015-0378-x PMid:26433388
Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: State-of-the-art and emerging therapies. Nat Rev Neurol. 2014;10(9):493-506. https://doi.org/10.1038/nrneurol.2014.141 PMid:25112508
Kimbrough DJ, Fujihara K, Jacob A, Lana-Peixoto MA, Leite MI, Levy M, et al. Treatment of neuromyelitis optica: Review and recommendations. Mult Scler Relat Disord. 2012;1(4):180-7. PMid:24555176
Kessler R, Mealy MA, Levy M. Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e269. https://doi.org/10.1212/nxi.0000000000000269 PMid:27508210
Mutch K, Methley A, Moore P, Jacob A. Life on hold: The experience of living with neuromyelitis optica. Disabil Rehabil. 2014;36(13):1100-7. https://doi.org/10.3109/09638288.2013.833301 PMid:24028351
Marignier R, Cobo Calvo A, Vukusic S. Neuromyelitis optica and neuromyelitis optica spectrum disorders. Curr Opin Neurol. 2017;30(3):208-15. https://doi.org/10.1097/wco.0000000000000455 PMid:28306572
Pfeuffer S, Strippel C, Wiendl H. NMO Spectrum disorders. Neurol Int Open. 2017;1:E36-47. https://doi.org/10.1055/s-0043-102456
European Medicines Agency. European Medicines Agency 16 June 2015 Report EMA/CHMP/SAWP/712652/2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2015/06/WC500188313.pdf. [Last accessed 2017 Aug ]
Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree BA, et al. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology. 2015;84(17):1805-15. PMid:25841026
Clinical Trial Gov. Available from: https://www.clinicaltrials.gov/ct2/ results? term=neuromyelitis+optica&Search=Apply&recrs=a&recrs=d&age_v=&gndr=&type=&rslt=. [Last accessed on 2018 Nov 18].
Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017;92(4):663-79. https://doi.org/10.1016/j.mayocp.2016.12.014 PMid:28385199
Kimura A, Kishimoto T. IL-6: Regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830-5. https://doi.org/10.1002/eji.201040391 PMid:20583029
Lin J, Li X, Xia J. Th17 cells in neuromyelitis optica spectrum disorder: A review. Int J Neurosci. 2016;126(12):1051-60. https://doi.org/10.3109/00207454.2016.1163550 PMid:26954363
Takeshita Y, Obermeier B, Cotleur AC. Effects of neuromyelitis optica IgG at the blood brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;4(1):e311. https://doi.org/10.1212/nxi.0000000000000311 PMid:28018943
Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;2019(12):1584-96. https://doi.org/10.1038/nm.3407 PMid:24309662
Yamamura T, Kleiter I, Fujihara K, Greenberg B, Jacob A, et al. A Double-blind Placebo-controlled Study of Satralizumab (SA237), a Recycling anti-IL-6 Receptor Monoclonal Antibody, as add-on Therapy for Neuromyelitis Optica Spectrum Disorder (NMOSD). Berlin, Germany: Presented at ECTRIMS 2018; October 10-12; 2018. https://doi.org/10.26226/morressier.5b7578695aff7400151f3258
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Ivan Barbov, Nikolina Tanovska, Igor Kuzmanovski, Tatjana Boshkova-Petkovska, Aleksandar Smokovski (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
